Charting a path toward combination therapy for Alzheimer's disease

Diane Stephenson, Dan Perry, Cynthia Bens, Lisa J. Bain, Donald Berry, Michael Krams, Reisa Sperling, David Dilts, Johan Luthman, Debra Hanna, John McKew, Robert Temple, F. Owen Fields, Stephen Salloway, Russell Katz

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalExpert Review of Neurotherapeutics
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2014

Keywords

  • Alzheimer's disease
  • Co-development
  • co-development
  • collaboration
  • combination therapy
  • novel therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Charting a path toward combination therapy for Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., McKew, J., Temple, R., Fields, F. O., Salloway, S., & Katz, R. (2014). Charting a path toward combination therapy for Alzheimer's disease. Expert Review of Neurotherapeutics, 15(1), 107-113. https://doi.org/10.1586/14737175.2015.995168